# Eslicarbazepine Acetate (BIA 2 093) as Therapy for Refractory Partial Seizures in Children

> **NCT00988156** · PHASE3 · COMPLETED · sponsor: **Bial - Portela C S.A.** · enrollment: 304 (actual)

## Conditions studied

- Partial Epilepsy in Children and Adolescents

## Interventions

- **DRUG:** Eslicarbazepine acetate (BIA 2-093)
- **DRUG:** Eslicarbazepine acetate

## Key facts

- **NCT ID:** NCT00988156
- **Lead sponsor:** Bial - Portela C S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12-07
- **Primary completion:** 2012-08-20
- **Final completion:** 2017-08-24
- **Target enrollment:** 304 (ACTUAL)
- **Last updated:** 2018-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00988156

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00988156, "Eslicarbazepine Acetate (BIA 2 093) as Therapy for Refractory Partial Seizures in Children". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00988156. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*